Chemoresistance in non-small-cell lung cancer: Can multidrug resistance markers predict the response of xenograft lung cancer models to chemotherapy?

European Journal of Cardio-thoracic Surgery

Volumn 40, Issue 1, 2011, Pages

  Merk, Johannes ^a   Rolff, Jana ^b   Dorn, Cornelia ^b   Leschber, Gunda ^a   Fichtner, Iduna ^b  

^a ELK Berlin Chest Hospital   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

Adjuvant chemotherapy; Lung cancer; Multidrug resistance; Xenograft

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CARBOPLATIN; CETUXIMAB; ERLOTINIB; ETOPOSIDE; GEMCITABINE; LUNG CANCER RELATED PROTEIN; MESSENGER RNA; MULTIDRUG RESISTANCE P GLYCOPROTEIN; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; PROTEIN; UNCLASSIFIED DRUG; VINORELBINE DITARTRATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CELL CULTURE; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG RESISTANCE; DRUG RESPONSE; HUMAN; HUMAN TISSUE; IN VIVO CULTURE; LUNG CANCER; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; TUMOR CELL; TUMOR GROWTH; TUMOR VOLUME; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MICE; MICE, SCID; NEOPLASM PROTEINS; P-GLYCOPROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79958001559     PISSN: 10107940     EISSN: 1873734X     Source Type: Journal    
DOI: 10.1016/j.ejcts.2011.02.010     Document Type: Article

References (25)

1. Arriagada R., Bergman B., Dunant A., Le Chevalier T., Pignon J.P., Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004, 350:351-360.
2. Tsuboi M., Ohira T., Saji H., Miyajima K., Kajiwara N., Uchida O., Usuda J., Kato H. The present status of postoperative adjuvant chemotherapy for completely resected non-small cell lung cancer. Ann Thorac Cardiovasc Surg 2007, 13:73-77.
3. Pignon J.P., Tribodet H., Scagliotti G.V., Douillard J.Y., Shepherd F.A., Stephens R.J., Dunant A., Torri V., Rosell R., Seymour L., Spiro S.G., Rolland E., Fossati R., Aubert D., Ding K., Waller D., Le Chevalier T. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008, 26:3552-3559.
4. Rosell R., Moran T., Queralt C., Porta R., Cardenal F., Camps C., Majem M., Lopez-Vivanco G., Isla D., Provencio M., Insa A., Massuti B., Gonzalez-Larriba J.L., Paz-Ares L., Bover I., Garcia-Campelo R., Moreno M.A., Catot S., Rolfo C., Reguart N., Palmero R., Sánchez J.M., Bastus R., Mayo C., Bertran-Alamillo J., Molina M.A., Sanchez J.J., Taron M. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009, 361:958-967. Spanish Lung Cancer Group.
5. Schinkel A.H., Jonker J.W. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 2003, 55:3-29.
6. Scheper R.J., Broxterman H.J., Scheffer G.L., Kaaijk P., Dalton W.S., van Heijningen T.H., van Kalken C.K., Slovak M.L., de Vries E.G., van der Valk P., Meijer C.J., Pinedo H.M. Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res 1993, 53:1475-1479.
7. Sharpless N.E., Depinho R.A. The mighty mouse: genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov 2006, 5:741-754.
8. Berger W., Elbling L., Hauptmann E., Micksche M. Expression of the multidrug resistance-associated protein (MRP) and chemoresistance of human non-small-cell lung cancer cells. Int J Cancer 1997, 73:84-93.
9. Ikuta K., Takemura K., Sasaki K., Kihara M., Nishimura M., Ueda N., Naito S., Lee E., Shimizu E., Yamauchi A. Expression of multidrug resistance proteins and accumulation of cisplatin in human non-small cell lung cancer cells. Biol Pharm Bull 2005, 28:707-712.
10. Berger W., Setinek U., Hollaus P., Zidek T., Steiner E., Elbling L., Cantonati H., Attems J., Gsur A., Micksche M. Multidrug resistance markers P-glycoprotein, multidrug resistance protein 1, and lung resistance protein in non-small cell lung cancer: prognostic implications. J Cancer Res Clin Oncol 2005, 131:355-363.
11. Chiou J.F., Liang J.A., Hsu W.H., Wang J.J., Ho S.T., Kao A. Comparing the relationship of Taxol-based chemotherapy response with P-glycoprotein and lung resistance-related protein expression in non-small cell lung cancer. Lung 2003, 181:267-273.
12. Angevin E., Glukhova L., Pavon C., Chassevent A., Terrier-Lacombe M.J., Goguel A.F., Bougaran J., Ardouin P., Court B.H., Perrin J.L., Vallancien G., Triebel F., Escudier B. Human renal cell carcinoma xenografts in SCID mice: tumorigenicity correlates with a poor clinical prognosis. Lab Invest 1999, 79:879-888.
13. Peterson J.K., Houghton P.J. Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development. Eur J Cancer 2004, 40:837-844.
14. Fichtner I., Rolff J., Soong R., Hoffmann J., Hammer S., Sommer A., Becker M., Merk J. Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers. Clin Cancer Res 2008, 14:6456-6468.
15. Merk J., Rolff J., Becker M., Leschber G., Fichtner I. Patient-derived xenografts of non-small-cell lung cancer: a pre-clinical model to evaluate adjuvant chemotherapy?. Eur J Cardiothorac Surg 2009, 36:454-459.
16. Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., Dancey J., Arbuck S., Gwyther S., Mooney M., Rubinstein L., Shankar L., Dodd L., Kaplan R., Lacombe D., Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247.
17. Rolff J., Dorn C., Merk J., Fichtner I. Response of patient-derived non-small cell lung cancer xenografts to classical and targeted therapies is not related to multidrug resistance markers. J Oncol 2009, 2009:814140.
18. Shepherd F.A. Chemotherapy for non-small cell lung cancer: have we reached a new plateau?. Semin Oncol 1999, 2:3-11.
19. Tiseo M., Franciosi V., Grossi F., Ardizzoni A. Adjuvant chemotherapy for non-small cell lung cancer: ready for clinical practice. Eur J Cancer 2006, 42:8-16.
20. Allen J.D., Van Dort S.C., Buitelaar M., van T.O., Schinkel A.H. Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein. Cancer Res 2003, 63:1339-1344.
21. Siva A.C., Raval-Fernandes S., Stephen A.G., LaFemina M.J., Scheper R.J., Kickhoefer V.A., Rome L.H. Up-regulation of vaults may be necessary but not sufficient for multidrug resistance. Int J Cancer 2001, 92:195-202.
22. Filipits M., Haddad V., Schmid K., Huynh A., Dunant A., Andre F., Brambilla E., Stahel R., Pignon J.P., Soria J.C., Popper H.H., Le C.T., Pirker R. Multidrug resistance proteins do not predict benefit of adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: International Adjuvant Lung Cancer Trial Biologic Program. Clin Cancer Res 2007, 13:3892-3898.
23. Hammer S., Sommer A., Fichtner I., Becker M., Rolff J., Merk J., Klar U., Hoffmann J. Comparative profiling of the novel epothilone, sagopilone, in xenografts derived from primary non-small cell lung cancer. Clin Cancer Res 2010, 16:1452-1465.
24. Dangles-Marie V., Pocard M., Richon S., Weiswald L.B., Assayag F., Saulnier P., Judde J.G., Janneau J.L., Auger N., Validire P., Dutrillaux B., Praz F., Bellet D., Poupon M.F. Establishment of human colon cancer cell lines from fresh tumors versus xenografts: comparison of success rate and cell line features. Cancer Res 2007, 67:398-407.
25. Singh M., Lima A., Molina R., Hamilton P., Clermont A.C., Devasthali V., Thompson J.D., Cheng J.H., Bou Reslan H., Ho C.C., Cao T.C., Lee C.V., Nannini M.A., Fuh G., Carano R.A., Koeppen H., Yu R.X., Forrest W.F., Plowman G.D., Johnson L. Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. Nat Biotechnol 2010, 28:585-593.